A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Trial Profile

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs MOR 208 (Primary) ; Bendamustine; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms B-MIND
  • Sponsors MorphoSys
  • Most Recent Events

    • 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, fourteen patients have been randomized to date.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Nov 2016 According to Xencor media release, following the Phase 2 safety evaluation the study is expected to transition into a pivotal Phase 3 part in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top